BC Extra | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
BC Week In Review | Jun 29, 2018
Financial News

Dementia fund closes £250M fund, names Grant CEO

The Dementia Discovery Fund (DDF) closed its £250 million ($331.1 million) fund. The close includes a new $60 million investment from AARP. The fund also hired Angus Grant as CEO, effective July 9. Grant was...
BC Extra | Jun 25, 2018
Financial News

Dementia fund closes £250M fund, names Grant CEO

The Dementia Discovery Fund (DDF) closed its £250 million ($331.1 million) fund. The close includes a new $60 million investment from AARP. The fund also hired Angus Grant as CEO, effective July 9. Grant was...
BioCentury | May 18, 2018
Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
BC Innovations | May 17, 2018
Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
BC Innovations | Aug 17, 2017
Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
BioCentury | Jun 9, 2017
Finance

Pedaling to the clinic

With lead candidate BT-1718 expected to enter the clinic this year, Bicycle Therapeutics Ltd. has padded its coffers with a £40 million ($51.3 million) series B to expand its pipeline of bicyclic peptides for cancer....
BC Week In Review | Jun 2, 2017
Financial News

Bicycle raises L40M in series B

On June 1, Bicycle Therapeutics Ltd. (Cambridge, U.K.) raised £40 million ($51.3 million) in a series B round led by new investor Vertex Ventures HC. New investors Cambridge Innovation Capital and Longwood Fund also participated,...
BC Extra | Jun 1, 2017
Financial News

Bicycle closes £40 million series B

Bicycle Therapeutics Ltd. (Cambridge, U.K.) raised £40 million ($51.3 million) in a series B round led by new investor Vertex Ventures HC. New investors Cambridge Innovation Capital and Longwood Fund also participated, as did existing...
BC Innovations | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
Items per page:
1 - 10 of 279
BC Extra | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
BC Week In Review | Jun 29, 2018
Financial News

Dementia fund closes £250M fund, names Grant CEO

The Dementia Discovery Fund (DDF) closed its £250 million ($331.1 million) fund. The close includes a new $60 million investment from AARP. The fund also hired Angus Grant as CEO, effective July 9. Grant was...
BC Extra | Jun 25, 2018
Financial News

Dementia fund closes £250M fund, names Grant CEO

The Dementia Discovery Fund (DDF) closed its £250 million ($331.1 million) fund. The close includes a new $60 million investment from AARP. The fund also hired Angus Grant as CEO, effective July 9. Grant was...
BioCentury | May 18, 2018
Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
BC Innovations | May 17, 2018
Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
BC Innovations | Aug 17, 2017
Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
BioCentury | Jun 9, 2017
Finance

Pedaling to the clinic

With lead candidate BT-1718 expected to enter the clinic this year, Bicycle Therapeutics Ltd. has padded its coffers with a £40 million ($51.3 million) series B to expand its pipeline of bicyclic peptides for cancer....
BC Week In Review | Jun 2, 2017
Financial News

Bicycle raises L40M in series B

On June 1, Bicycle Therapeutics Ltd. (Cambridge, U.K.) raised £40 million ($51.3 million) in a series B round led by new investor Vertex Ventures HC. New investors Cambridge Innovation Capital and Longwood Fund also participated,...
BC Extra | Jun 1, 2017
Financial News

Bicycle closes £40 million series B

Bicycle Therapeutics Ltd. (Cambridge, U.K.) raised £40 million ($51.3 million) in a series B round led by new investor Vertex Ventures HC. New investors Cambridge Innovation Capital and Longwood Fund also participated, as did existing...
BC Innovations | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
Items per page:
1 - 10 of 279